These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 33545014)

  • 1. Coronavirus (SARS-CoV-2): a systematic review for potential vaccines.
    Bhatta M; Nandi S; Dutta S; Saha MK
    Hum Vaccin Immunother; 2022 Dec; 18(1):1865774. PubMed ID: 33545014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.
    Checcucci E; Piramide F; Pecoraro A; Amparore D; Campi R; Fiori C; Elhage O; Kotecha P; Vyakarnam A; Serni S; Dasgupta P; Porpiglia F
    Panminerva Med; 2022 Mar; 64(1):72-79. PubMed ID: 32456404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.
    Malik JA; Ahmed S; Mir A; Shinde M; Bender O; Alshammari F; Ansari M; Anwar S
    J Infect Public Health; 2022 Feb; 15(2):228-240. PubMed ID: 35042059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines.
    Ashmawy R; Hamdy NA; Elhadi YAM; Alqutub ST; Esmail OF; Abdou MSM; Reyad OA; El-Ganainy SO; Gad BK; Nour El-Deen AE; Kamal A; ElSaieh H; Elrewiny E; Shaaban R; Ghazy RM
    J Prim Care Community Health; 2022; 13():21501319221089255. PubMed ID: 35400233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 vaccines: Clinical endpoints and psychological perspectives: A literature review.
    Malik JA; Aroosa M; Ahmed S; Shinde M; Alghamdi S; Almansour K; Hagbani TA; Alanazi MS; Anwar S
    J Infect Public Health; 2022 May; 15(5):515-525. PubMed ID: 35429790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies.
    Payandeh Z; Mohammadkhani N; Nabi Afjadi M; Khalili S; Rajabibazl M; Houjaghani Z; Dadkhah M
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):899-910. PubMed ID: 33307883
    [No Abstract]   [Full Text] [Related]  

  • 10. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies.
    Farooqi T; Malik JA; Mulla AH; Al Hagbani T; Almansour K; Ubaid MA; Alghamdi S; Anwar S
    J Infect Public Health; 2021 Oct; 14(10):1299-1312. PubMed ID: 34429257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Super-rapid race for saving lives by developing COVID-19 vaccines.
    Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A
    J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
    Canaday DH; Gravenstein S
    Clin Infect Dis; 2021 Feb; 72(3):513-514. PubMed ID: 33527123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?
    Shi Y; Guo M; Yang W; Liu S; Zhu B; Yang L; Yang C; Liu C
    Expert Rev Vaccines; 2021 Apr; 20(4):375-383. PubMed ID: 33787439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
    Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
    Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.